The drastic cost-cutting move followa the deaths of two teenagers that forced the company to restrict usage of its gene ...

This is a developing story and will be updated as more information becomes available. | Sarepta Therapeutics has laid off 500 staffers, or 36% of its workforce, as part of a strategic restructuring ...

The company is also pausing research for several treatments it has been developing for another form of muscular dystrophy.

Investing.com -- Sarepta Therapeutics (NASDAQ: SRPT) stock soared 36% in after-hours trading Wednesday after the biotech company announced a major strategic restructuring plan designed to ensure ...

Sarepta Therapeutics faces a challenging period as it navigates recent setbacks with its groundbreaking gene therapy, leading ...

AI-based digital twin modeling predicts patient-specific decline, addressing key trial design and biomarker challenges in FSHD ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is one of the 10 Best Small-Cap Stocks to Buy According to Billionaires. On July 10, JPMorgan lowered its price target for Sarepta Therapeutics, Inc.

New research has identified the enzyme glutamate dehydrogenase 1 (GLUD1) as a new therapeutic target for Duchenne muscular dystrophy (DMD). In preclinical DMD mouse models, investigators demonstrated ...

New research has identified the enzyme glutamate dehydrogenase 1 (GLUD1) as a new therapeutic target for Duchenne muscular dystrophy (DMD). In ...

Tue 15 Jul 5.47pm • Leeds is at the forefront of attempts to find a cure for Duchenne Muscular Dystrophy with a major cash boost announced for clinical trials.

Capricor plans to resubmit its application for the approval of deramiocel for DMD after the FDA declined to accept the ...